Absolute ethanol renal angioinfarction for control of hypertension

I W Klimberg1, D R Locke, I F Hawkins

  • 1Department of Surgery, University of Florida College of Medicine, Gainesville.

Urology
|February 1, 1989
PubMed

Insights

Ethanol renal angioinfarction effectively treated severe hypertension in six patients, improving blood pressure and reducing medication needs. This minimally invasive procedure offers a safe alternative for high-risk individuals.

Area of Science:

  • Interventional Radiology
  • Nephrology
  • Cardiology

Background:

  • Medically uncontrollable hypertension poses significant health risks.
  • Renal vein renin levels can indicate renovascular hypertension.
  • Nephrectomy is a drastic measure for severe, refractory hypertension.

Purpose of the Study:

  • To evaluate the efficacy and safety of ethanol renal angioinfarction for severe hypertension.
  • To assess the impact of the procedure on blood pressure and medication requirements.
  • To determine if ethanol angioinfarction is a viable alternative to nephrectomy.

Main Methods:

  • Six patients with severe hypertension underwent ethanol renal angioinfarction (11 renal units).
  • Pre-ablation blood pressure and renal vein renin levels were recorded.
  • Patients were followed for a mean of 51 months post-procedure.

Main Results:

  • All 6 patients experienced improved hypertension post-procedure.
  • Complete resolution of systemic hypertension occurred in 4 patients.
  • No major complications were associated with ethanol injection.

Conclusions:

  • Transcatheter renal ablation with ethanol is a safe and effective treatment for severe hypertension.
  • This procedure is a potential alternative to nephrectomy in selected high-risk patients.
  • Ethanol angioinfarction offers a minimally invasive option for managing refractory hypertension.

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...